Skip to main content

Table 3 Patients’ characteristics

From: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer

  RAS p21
Total RAS p21 elevated
n (%)
p-value
Overall 251 29 (12%)  
ER status    0.611
 Negative 76 10 (13%)  
 Positive 174 19 (11%)  
PR status    0.358
 Negative 101 14 (14%)  
 Positive 149 15 (10%)  
HER2 status    0.873
 Negativea 143 18 (13%)  
 Positiveb 76 9 (12%)  
Tumor subtype    0.728
 Triple-negative 37 6 (16%)  
 HR-positive HER2-negative 106 12 (11%)  
 HER2-positive 76 9 (12%)  
Metastatic site    0.482
 Visceral 98 13 (13%)  
 Bone 35 2 (6%)  
 Both 118 14 (12%)
Extent of metastatic disease    0.768
 One site 84 9 (11%)  
 Multiple sites 167 20 (12%)  
Therapeutic setting    0.249
 1st-line 98 8 (8%)  
 2nd-line 66 11 (17%)  
 3rd-line or more 86 10 (12%)  
Grading    0.604
 G1 5 1 (20%)  
 G2 129 13 (10%)  
 G3 103 14 (14%)
Circulating tumor cells    0.101
  < 5 CTCs / 7.5 ml 122 17 (14%)  
  ≥ 5 CTCs / 7.5 ml 121 9 (7%)  
  1. Abbreviations: HR hormone receptor
  2. aIHC score: 0 /+ 1 or FISH negative
  3. bIHC score: + 3 or FISH positive